<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35445431</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>200</EndPage><MedlinePgn>195-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26375</ELocationID><Abstract><AbstractText>Oxidative stress (OS) induces inflammation, which in turn exacerbates OS and the expression of acute phase proteins (APPs). Regulatory T lymphocyte (Treg) therapy was assessed for suppression of OS and APP responses in longitudinal serum samples from subjects with amyotrophic lateral sclerosis (ALS) enrolled in a phase I clinical trial. The first round of Treg therapy suppressed levels of oxidized low-density lipoprotein (ox-LDL). During a 6-month washout period, ox-LDL levels increased. A second round of therapy again suppressed ox-LDL levels and then rose following the cessation of treatment. Serum levels of APPs, soluble CD14, lipopolysaccharide binding protein, and C-reactive protein, were stabilized during Treg administrations, but rose during the washout period and again after therapy was discontinued. Treg therapy potentially suppresses peripheral OS and the accompanying circulating pro-inflammatory induced APPs, both of which may serve as peripheral candidates for monitoring efficacies of immunomodulating therapies. ANN NEUROL 2022;92:195-200.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beers</LastName><ForeName>David R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-8757-3500</Identifier><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thonhoff</LastName><ForeName>Jason R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faridar</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thome</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Weihua</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Shixiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appel</LastName><ForeName>Stanley H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000209">Acute-Phase Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000209" MajorTopicYN="N">Acute-Phase Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050378" MajorTopicYN="N">T-Lymphocytes, Regulatory</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>DRB declares a conflict of interest as a consultant with Implicit Bioscience and Coya Therapeutics, Inc. ADT declares a conflict of interest as a consultant with Coya Therapeutics, Inc. SHA declares a conflict of interest as a consultant with Implicit Bioscience and scientific advisory board chair of Coya Therapeutics, Inc. The remaining authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>21</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35445431</ArticleId><ArticleId IdType="pmc">PMC9545429</ArticleId><ArticleId IdType="doi">10.1002/ana.26375</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol 2019;18:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, et al. Regulatory T&#x2010;lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med 2013;5:64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et al. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2017;2:e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, et al. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol 2017;74:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, et al. Association of regulatory T&#x2010;cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol 2018;75:681&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 2010;48:629&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, et al. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep 2020;10:15295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="pubmed">32943739</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Thonhoff JR, et al. Serum programmed cell death proteins in amyotrophic lateral sclerosis. Brain Behav Immun Health 2021;12:100209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8474632</ArticleId><ArticleId IdType="pubmed">34589734</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, et al. Expanded autologous regulatory T&#x2010;lymphocyte infusions in ALS: a phase I, first&#x2010;in&#x2010;human study. Neurol Neuroimmunol Neuroinflamm 2018;5:e465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsuliman A, Appel SH, Beers DR, et al. A robust, good manufacturing practice&#x2010;compliant, clinical&#x2010;scale procedure to generate regulatory T cells from patients with amyotrophic lateral sclerosis for adoptive cell therapy. Cytotherapy 2016;18:1312&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pubmed">27497700</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreto J, Karathanasis SK, Remaley A, Sposito AC. Role of LOX&#x2010;1 (lectin&#x2010;like oxidized low&#x2010;density lipoprotein receptor 1) as a cardiovascular risk predictor: mechanistic insight and potential clinical use. Arterioscler Thromb Vasc Biol 2021;41:153&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9186447</ArticleId><ArticleId IdType="pubmed">33176449</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha&#x2010;Oliveira T, Montezinho L, Mendes C, et al. Oxidative stress in amyotrophic lateral sclerosis: pathophysiology and opportunities for pharmacological intervention. Oxidative Med Cell Longev 2020;2020:5021694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683149</ArticleId><ArticleId IdType="pubmed">33274002</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Zhao W. Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation mediated neurodegeneration. Curr Opin Neurol 2021;34:765&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">34402459</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z, Zhou H, Peng Y, et al. Expression and significance of plasma 3&#x2010;NT and ox&#x2010;LDL in patients with Alzheimer's disease. Genet Mol Res 2014;13:8428&#x2013;8435.</Citation><ArticleIdList><ArticleId IdType="pubmed">25366737</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirillo A, Norata GD, Luigi Catapano AL. LOX&#x2010;1, OxLDL, and atherosclerosis. Mediat Inflamm 2013;2013:152786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3723318</ArticleId><ArticleId IdType="pubmed">23935243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofmann A, Brunssen C, Wolk S, et al. Soluble LOX&#x2010;1: A novel biomarker in patients with coronary artery disease, stroke, and acute aortic dissection? J Am Heart Assoc 2020;9:e013803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988168</ArticleId><ArticleId IdType="pubmed">31902328</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson EP, Henry YK, Henkel JS, et al. Increased lipid peroxidation in sera of ALS patients&#x2014;a potential biomarker of disease burden. Neurologija 2004;62:1758&#x2013;1765.</Citation><ArticleIdList><ArticleId IdType="pubmed">15159474</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D, Moreau C, Kyheng M, et al. A ferroptosis&#x2013;based panel of prognostic biomarkers for amyotrophic lateral sclerosis. Sci Rep 2019;9:2918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393674</ArticleId><ArticleId IdType="pubmed">30814647</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D, Rogowski O, Berliner S, et al. Low&#x2010;grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2009;119:383&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">18976328</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>